Ofev Plus Sildenafil Isn’t Effective for IPF Patients with Poor Lung Function

  • Research and Development

    Ofev Plus Sildenafil Isn’t Effective for IPF Patients with Poor Lung Function

    Posted by Pulmonary Fibrosis News Moderator on October 9, 2018 at 1:13 pm

    Combining Ofev (nintedanib, marketed by Boehringer Ingelheim) with sildenafil does not offer additional clinical benefits when compared to Ofev treatment alone regarding quality of life and lung function in patients with idiopathic pulmonary fibrosis (IPF) and a very poor lung function, a Phase 3 study demonstrates.

    The study, “Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis,” was published in the The New England Journal of Medicine.

    Read a summary of the Phase 3 study and its findings here.

    Have you been treated with Ofev and/or sildenafil? Tell us about your experience.

    replied 5 years, 11 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .